Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ku Leuven
Leuven, Belgium
- Ospedale Niguarda Ca Granda
Milan, Italy
- Second University of Naples
Naples, Italy
- the Netherlands Cancer Institute
Amsterdam, Netherlands
- Institut Català D'Oncologia
Barcelona, Spain
- Vall D'Hebron Institute of Oncology
Barcelona, Spain
- Fundación Investigación Clínico de Valencia
Valencia, Spain
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Nov 2017
- Primary completion
- 27 Nov 2020
- Completion
- 27 Nov 2020
- Last update posted
- 1 Oct 2025
- Registered enrollment
- 46
- Registry id
- NCT02982694
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.